A trial of intranasal remifentanil for painful ophthalmic procedures.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002460-26-GB

Enrollment

Registered

2006-05-22

Start date

2006-07-21

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painful ophthalmic procedures

Interventions

Trade Name: Ultiva Product Name: N/A Product Code: N/A Pharmaceutical Form: Powder and solvent for solution for infusion Pharmaceutical form of the placebo: Nasal spray* Route of administration of the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing panretinal laser photocoagulation for diabetic retinopathy or cryotherapy for retinal holes. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Under 18 yrs age; under 50kg body weight.

Design outcomes

Primary

Measure	Time frame
Main Objective: Determine whether effective pain relief is achieved;Secondary Objective: Acceptability to patients of the method of delivery;Primary end point(s): 78 patients teated.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026